Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood ratios, and Bayes theorem

Chest

Volumn 144, Issue 4, 2013, Pages 1269-1275

  Raschke, Robert A ^a,b   Curry, Steven C ^a,b,c   Warkentin, Theodore E ^d,e   Gerkin, Richard D ^a,b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885110469     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2712     Document Type: Article

References (32)

1. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011 ;2011: 143-149.
2. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007; 82 (12): 1037-1043.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med. 1995; 332 (20): 1330-1335.
4. Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost. 2004; 30 (3): 359-368.
5. Arepally GM, Hursting MJ. Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. J Thromb Thrombolysis. 2008; 26 (1): 55-61.
6. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007; 5 (8): 1666-1673.
7. Morel-Kopp MC, Aboud M, Tan CW, Kulathilake C, Ward C. Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays. Int J Lab Hematol. 2011; 33 (3): 245-250.
8. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti- PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006; 76 (5): 420-426.
9. Palomo I, Pereira J, Alarcón M, et al. Prevalence of heparininduced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal. 2005; 19 (5): 189-195.
10. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJH. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2009; 7 (8): 1260-1265.
11. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 2008; 100 (4): 678-684.
12. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008; 6 (8): 1304-1312.
13. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003; 23 (6): 745-753.
14. Radaideh SM, Frenkel EP, Dowell JE, Sarode R, Shen YM. Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA. Clin Appl Thromb Hemost. 2012; 18 (2): 215-217.
15. Bakchoul T, Giptner A, Bein G, Santoso S, Sachs UJH. Performance characteristics of two commercially available IgGspecific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res. 2011; 127 (4): 345-348.
16. Shelat SG, Tomaski A, Pollak ES. Serologic results in. 1000 patients with suspected heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2008; 14 (4): 410-414.
17. Wanat M, Fitousis K, Hall J, Rice L. PF4/Heparin antibody testing and treatment of heparin-induced thrombocytopenia in the intensive care unit. Clin Appl Thromb Hemost. 2013; 19: 297-302.
18. Weiss BM, Shumway NM, Howard RS, Ketchum LK, Reid TJ. Optical density values correlate with the clinical probability of heparin induced thrombocytopenia. J Thromb Thrombolysis. 2008; 26 (3): 243-247.
19. Baroletti S, Hurwitz S, Conti NAS, Fanikos J, Piazza G, Goldhaber SZ. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012; 125 (1): 44-49.
20. Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg. 2011; 213 (1): 10-17.
21. College of American Pathologists. Surveys 2012: heparininduced thrombocytopenia. Participant summary. Northfield, IL: College of American Pathologists; 2012 ;CGS5-A: 1-5.
22. Peirce JC, Cornell RG. Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making. 1993; 13 (2): 141-151.
23. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4 (4): 759-765.
24. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012 ;120(20): 4160-4167.
25. Warkentin TE, Cook RJ. Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia. J Lab Med. 2011; 35 (1): 45-54.
26. McFarland J, Lochowicz A, Aster R, Chappell B, Curtis B. Improv ing the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia. Am J Hematol. 2012; 87 (8): 776-781.
27. Levine RL, Hergenroeder GW, Francis JL, Miller CC, Hursting MJ. Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study. J Thromb Thrombolysis. 2010; 30 (2): 142-148.
28. Strutt JK, Mackey JE, Johnson SM, Sylvia LM. Assessment of the 4Ts pretest clinical scoring system as a predictor of heparininduced thrombocytopenia. Pharmacotherapy. 2011; 31 (2): 138-145.
29. Bryant A, Low J, Austin S, Joseph JE. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol. 2008; 143 (5): 721-726.
30. Denys B, Stove V, Philippé J, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res. 2008; 123(1): 137-145.
31. Arepally GM, Ortel TL. Clinical practice. Heparininduced thrombocytopenia. N Engl J Med. 2006; 355 (8): 809-817.
32. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009; 113 (20): 4963-4969.